WindRose Health Investors has made a strategic investment in Stellus Rx, a technology-enabled, value-based pharmacy care management platform focused on improving clinical outcomes while reducing healthcare costs. The terms of the transaction were not disclosed.
Based in Plano, Texas, Stellus Rx delivers personalized, pharmacist-led services designed to simplify the medication journey for patients and healthcare providers. The company partners with providers, payors, employers, and other risk-bearing entities to enhance medication value through improved adherence, proactive outreach, timely clinical interventions, ongoing pharmacist support, and convenient dispensing services. Stellus Rx’s model is particularly focused on patients with chronic and complex conditions, where medication optimization can have a meaningful impact on both outcomes and total cost of care.
The investment from WindRose Health Investors will support Stellus Rx’s continued expansion as it scales its clinical and operational capabilities and broadens access to its platform across additional patient populations nationwide. The partnership reflects WindRose’s focus on backing healthcare services businesses with proven, scalable models that deliver cost-effective solutions across the care continuum.
WindRose Health Investors is a New York-based healthcare private equity firm with approximately $7 billion in assets under management. The firm invests in healthcare services companies with profitable business models and demonstrated operational strength, supporting growth initiatives across the United States. WindRose’s investment in Stellus Rx aligns with its strategy of partnering with companies that improve healthcare quality while lowering total medical costs.
Support: Stellus Rx was advised on the transaction by Robert W. Baird & Co. as financial advisor and Goodwin Procter LLP as legal advisor. WindRose Health Investors was advised by McDermott Will & Schulte LLP as legal advisor and TripleTree as financial advisor.
KEY QUOTES:
“This partnership with WindRose marks a significant milestone for Stellus Rx, as we continue to scale our pharmacist-led platform and ensure that even more people receive the full benefit and value from their prescribed medications. **WindRose’s deep healthcare expertise and collaborative approach make them an ideal partner. We look forward to our work together, as we continue to help millions of people achieve better health outcomes through a fully supported medication experience.”
Tony Willoughby, Chief Executive Officer, Stellus Rx
“Stellus Rx is a highly differentiated, technology-enabled platform with a proven ability to improve healthcare quality and lower total medical costs **We are excited to partner with Tony and the Stellus Rx team to scale a model that combines clinical excellence with value-based outcomes.”
Alex Buzik, Partner, WindRose Health Investors
